You are here

Antimicrobial Efflux Pumps and Mycobacterium Tuberculosis Drug Tolerance: Evolutionary Considerations.

TitleAntimicrobial Efflux Pumps and Mycobacterium Tuberculosis Drug Tolerance: Evolutionary Considerations.
Publication TypeJournal Article
Year of Publication2012
AuthorsSzumowski, JD, Adams, KN, Edelstein, PH, Ramakrishnan, L
JournalCurr Top Microbiol Immunol
Date Published2012 Dec 16
ISSN0070-217X
Abstract

The need for lengthy treatment to cure tuberculosis stems from phenotypic drug resistance, also known as drug tolerance, which has been previously attributed to slowed bacterial growth in vivo. We discuss recent findings that challenge this model and instead implicate macrophage-induced mycobacterial efflux pumps in antimicrobial tolerance. Although mycobacterial efflux pumps may have originally served to protect against environmental toxins, in the pathogenic mycobacteria, they appear to have been repurposed for intracellular growth. In this light, we discuss the potential of efflux pump inhibitors such as verapamil to shorten tuberculosis treatment by their dual inhibition of tolerance and growth.

DOI10.1007/82_2012_300
Alternate JournalCurr. Top. Microbiol. Immunol.
PubMed ID23242857
Grant ListDP1 MH099901 / MH / NIMH NIH HHS / United States
R01 AI036396 / AI / NIAID NIH HHS / United States
R37 AI054503 / AI / NIAID NIH HHS / United States